On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Director Luke Evnin reported selling shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) common stock over three days, with the transactions totaling approximately $61,787. The sales occurred between ...
Werewolf Therapeutics (NASDAQ:HOWL) just reported results for the second quarter of 2024. Werewolf Therapeutics reported earnings per share of -43 cents. This was below the analyst estimate for EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results